ASH News Daily 2017 - Issue 1 - C-19

patients for signs or symptoms of neurologic toxicities for 4 weeks after[see
infusion andSummary
treat promptly
[see Reactions
Summary
of Adverse
Reactions
in atTreated
Least 10%
the Patients Treated with YESCARTA
of Adverse
Observed
in at Least
10% ofObserved
the Patients
withofYESCARTA
Management of Severe Adverse Reactions
. (2.3); Neurologic Toxicities].
in Study 1 (continued)
in Study 1 (continued)

Because
5.3ofYESCARTA
the risk of CRS
REMS:
andBecause
neurologic
of the
toxicities,
risk ofYESCARTA
CRS and neurologic
is availabletoxicities,
only through
YESCARTA
a
is available only through a
Adverse Reaction Any Grade Grades 3 or Any Grade Grades 3 or
Adverse Reaction
restricted program under a Risk Evaluation and Mitigation Strategy (REMS)
[see
called
Boxed
the YESCARTA REMS [see Boxed
(%)
Higher (%)
(%)
Higher (%)
Warning and Warnings.and
ThePrecautions
required components
(5.1 and 5.2)].
of the
TheYESCARTA
required components
REMS are: of the YESCARTA REMS are:
1
1
19
19
Musculoskeletal
and connective
Motor and
dysfunction
Musculoskeletal
connective
Motor dysfunction
* Healthcare facilities that dispense and administer YESCARTA must be enrolled and comply
with the REMS
2
2
17
17
disorders
Pain in extremity
tissue disorders
Pain in extremity
requirements. Certified healthcare facilities must have on-site, immediate access to tissue
tocilizumab,
and
1
1
15
Back pain
Back pain 15
ensure that a minimum of two doses of tocilizumab are available for each patient for infusion within
1
1
14
Muscle pain
Muscle pain 14
2 hours after YESCARTA infusion, if needed for treatment of CRS.
0
0
10
Arthralgia
Arthralgia 10
* Certified healthcare facilities must ensure that healthcare providers who prescribe, dispense or administer
YESCARTA are trained about the management of CRS and neurologic toxicities.
29
29
57
57
Nervous system disorders Nervous system
Encephalopathy
disorders
Encephalopathy
1
1
45
Headache
Headache 45
Further information is available at www.YescartaREMS.com or 1-844-454-KITE (5483).
2
2
31
31
Tremor
Tremor
5.4 Hypersensitivity
Allergic reactionsReactions:
may occur with
Allergic
the reactions
infusion ofmay
YESCARTA.
occur with
Serious
the infusion of YESCARTA. Serious
1
1
21
Dizziness
Dizziness 21
hypersensitivity reactions including anaphylaxis, may be due to dimethyl sulfoxide (DMSO) or residual
6
6
18
18
Aphasia
Aphasia
gentamicin in YESCARTA.
Psychiatric disorders
17
6
Psychiatric Delirium
disorders
Delirium
17
6
Severe
5.5orSerious
life-threatening
Infections:
infections
Severe occurred
or life-threatening
in patientsinfections
after YESCARTA
occurredinfusion.
in patients after YESCARTA infusion.
11
11
32
32
Respiratory,
and Respiratory,Hypoxia
thoracic and
Hypoxia
In Study 1, infections (all grades) occurred in 38% of patients. Grade 3 or higher infections
occurredthoracic
in
0
0
30
30
disorders
mediastinalCough
disorders
Cough
23% of patients. Grade 3 or higher infections with an unspecified pathogen occurred inmediastinal
16% of patients,
3
3
19
19
Dyspnea
Dyspnea
bacterial infections in 9%, and viral infections in 4%. YESCARTA should not be administered to patients with
2
2
13
13
Pleural effusion
Pleural effusion
clinically significant active systemic infections. Monitor patients for signs and symptoms of infection before
and after YESCARTA infusion and treat appropriately. Administer prophylactic anti-microbials
according
to disordersRenal and urinary
Renal and
urinary
Renal insufficiency
12
5
disorders
Renal insufficiency
12
5
local guidelines. Febrile neutropenia was observed in 36% of patients after YESCARTA infusion and may
be concurrent with CRS. In the event of febrile neutropenia, evaluate for infection and manage
broad
15
15
57
Vascularwith
disorders
Hypotension
Vascular disorders
Hypotension 57
spectrum antibiotics, fluids and other supportiveViral
careReactivation:
as medically Hepatitis
indicated. Viral Reactivation: Hepatitis
6
6
15
Hypertension
Hypertension15
B virus (HBV) reactivation, in some cases resulting in fulminant hepatitis, hepatic failure and death, can
1
1
10
Thrombosis
Thrombosis 10
occur in patients treated with drugs directed against B cells. Perform screening for HBV, HCV, and HIV in
The following events were also counted
in the incidence
CRS:also
tachycardia,
fever,
chills,tachycardia,
hypoxemia,arrhythmia,
renal insufficiency,
The following
events of
were
counted inarrhythmia,
the incidence
of CRS:
fever, chills, hypoxemia, renal insufficiency,
accordance with clinical guidelines before collection of cells for manufacturing.
and hypotension. For a complete listand
of events
that contributed
to the list
incidence
of certain
adverse reactions,
please of
seecertain
footnote
hypotension.
For a complete
of events
that contributed
to the incidence
adverse reactions, please see footnote

Patients
5.6 Prolonged
may exhibit
Cytopenias:
cytopenias
Patients
for several
may exhibit
weeks cytopenias
following lymphodepleting
for several weeks following
lymphodepleting
below Table 3 in Section 6.1 of the Full
Prescribing
below
Table 3 inInformation.
Section 6.1 of the Full Prescribing Information.
chemotherapy and YESCARTA infusion. In Study 1, Grade 3 or higher cytopenias not resolved by Day 30
Other
clinically
important
adverse
reactions
that
occurred
in lessreactions
than 10%
of occurred
patients treated
with 10% of patients treated with
Other
clinically
important
adverse
that
in less than
following YESCARTA infusion occurred in 28% of patients and included thrombocytopenia (18%), neutropenia
YESCARTA include the following:
blood and
lymphatic
system disorders:
(2%);disorders:
cardiac coagulopathy (2%); cardiac
YESCARTA
include
the following:
blood and coagulopathy
lymphatic system
(15%), and anemia (3%). Monitor blood counts after YESCARTA infusion.
disorders:
cardiac failure (6%)disorders:
and cardiac
arrestfailure
(4%);(6%)
immune
system disorders:
cardiac
and cardiac
arrest (4%);hemophagocytic
immune system disorders: hemophagocytic
5.7 B-cell
Hypogammaglobulinemia:
aplasia and hypogammaglobulinemia
B-cell aplasia and
canhypogammaglobulinemia
occur in patients
can occur
in patients
activation syndrome (HLH/MAS)
(1%), hypersensitivity
(1%); infections
lymphohistiocytosis/macrophage
activation
syndrome (HLH/MAS)
(1%), hypersensitivity (1%); infections
receiving treatment with YESCARTA. In Study 1, hypogammaglobulinemia occurred inlymphohistiocytosis/macrophage
15% of patients.
and infestations
disorders: fungal
infections (5%);
nervous
system
disorders:
ataxia
(6%),system
seizuredisorders:
(4%), ataxia (6%), seizure (4%),
and infestations
disorders:
fungal
infections
(5%);
nervous
Monitor immunoglobulin levels after treatment with YESCARTA and manage using infection
precautions,
dyscalculia
and myoclonus
(2%); respiratory,
thoracic and(2%);
mediastinal
disorders:
pulmonary
edema disorders: pulmonary edema
dyscalculia
(2%), and myoclonus
respiratory,
thoracic
and mediastinal
antibiotic prophylaxis and immunoglobulin replacement. The safety of immunization with
live viral(2%),
vaccines
(9%);vaccines
skin andissubcutaneous
tissueskin
disorders:
rash (9%); vascular
disorders:rash
capillary
syndrome
(3%).capillary leak syndrome (3%).
(9%);
and subcutaneous
tissue disorders:
(9%);leak
vascular
disorders:
during or following YESCARTA treatment has not been studied. Vaccination with live virus
not
Grade
3 orYESCARTA
4 Laboratory Abnormalities
in Abnormalities
≥ 10% of Patients
in Study
Grade 3 or 4Occurring
Laboratory
Occurring
in 1≥ 10% of Patients in Study 1
recommended for at least 6 weeks prior to the start of lymphodepleting chemotherapy,
during
Following Treatment with YESCARTA
on CTCAE
(N=108) based on CTCAE (N=108)
Following based
Treatment
with YESCARTA
treatment, and until immune recovery following treatment with YESCARTA.
Lymphopenia
100%,
Leukopenia
96%, Neutropenia
93%, Anemia
66%,
Thrombocytopenia
58%,66%, Thrombocytopenia 58%,
Lymphopenia
100%, Leukopenia
96%,
Neutropenia
93%, Anemia
5.8Patients
Secondary
treated
Malignancies:
with YESCARTA
Patients
may develop
treatedsecondary
with YESCARTA
malignancies.
may develop
Monitor
secondary
malignancies.
Monitor
50%, Hyponatremia
19%, Uric50%,
acidHyponatremia
increased 13%,
Direct
increased
13%,
Hypophosphatemia
19%,
UricBilirubin
acid increased
13%,
Direct Bilirubin increased 13%,
life-long for secondary malignancies. In the event that a secondary malignancy occurs,Hypophosphatemia
contact Kite at
increased
Hypokalemia 10%,
Alanine10%.
Aminotransferase increased 10%.
1-844-454-KITE (5483) to obtain instructions on patient samples to collect for testing. Hypokalemia 10%, Alanine Aminotransferase
6.2events,
Immunogenicity:
has the potential toYESCARTA
induce anti-product
antibodies.
The immunogenicity
6.2 Immunogenicity:
has the potential
to induce
anti-product antibodies. The immunogenicity
5.9 Effects on Ability toDue
Drive
to the
andpotential
Use Machines:
for neurologic
Due toevents,
the potential
including
for neurologic
including YESCARTA
using an enzyme-linked
immunosorbent
assay (ELISA) immunosorbent
for the detectionassay
of (ELISA) for the detection of
of YESCARTA
has been evaluated
using an enzyme-linked
altered mental status or seizures, patients receiving YESCARTA are at risk for altered oforYESCARTA
decreasedhas been evaluated
binding to
antibodies
theantibodies
originatingagainst
antibody
of thethe
anti-CD19
CAR.antibody
Three patients
tested positive
binding
FMC63,
originating
of the anti-CD19
CAR. Three patients tested positive
consciousness or coordination in the 8 weeks following YESCARTA infusion. Advise patients
refrain against FMC63,
for pre-dose
anti-FMC63 antibodies
at baseline
and Months
1, 3, orat6baseline
in Studyand
1. There
is no
evidence
that 1. There is no evidence that
for pre-dose
anti-FMC63
antibodies
Months
1, 3,
or 6 in Study
from driving and engaging in hazardous occupations or activities, such as operating heavy
or potentially
the kinetics of initial expansionthe
andkinetics
persistence
of YESCARTA,
or the
safety or effectiveness
of initial
expansion and
persistence
of YESCARTA, of
orYESCARTA,
the safety orwas
effectiveness of YESCARTA, was
dangerous machinery, during this initial period.
altered in these patients.
altered in these patients.
The6following
ADVERSEadverse
REACTIONS:
reactions
Theare
following
described
adverse
in Warnings
reactions
andarePrecautions:
described in Warnings and Precautions:
USE IN SPECIFIC
POPULATIONS
8 USE IN SPECIFIC POPULATIONS
Cytokine Release Syndrome, Neurologic Toxicities, Hypersensitivity Reactions, Serious8 Infections,
Prolonged
Cytopenias, Hypogammaglobulinemia.
8.1 Pregnancy: Risk Summary:
are no Risk
available
data with
YESCARTA
use in pregnant
No use in pregnant women. No
8.1 There
Pregnancy:
Summary:
There
are no available
data withwomen.
YESCARTA
animalconditions,
reproductive and developmental
toxicity studies
have been conducted
with YESCARTA
to conducted
assess with YESCARTA to assess
animal reproductive
and developmental
toxicity studies
have been
6.1Because
Clinical clinical
Trials Experience:
trials are conducted
Becauseunder
clinical
widely
trialsvarying
are conducted
conditions,
under widely varying
whether
can in
cause
when itadministered
to aharm
pregnant
It is nottoknown
if YESCARTA
whether
can cause fetal
whenwoman.
administered
a pregnant
woman.has
It is not known if YESCARTA has
adverse reaction rates observed in the clinical trials of a drug cannot be directly compared
to itrates
the fetal harm
the potential
to be transferredthe
to potential
the fetus.toBased
on the mechanism
of action,
cross if the transduced cells cross
be transferred
to the fetus.
Based ifonthe
thetransduced
mechanismcells
of action,
clinical trials of another drug and may not reflect the rates observed in practice. The safety
data described
the placenta,
they may causethe
fetalplacenta,
toxicity, they
including
B-cell fetal
lymphocytopenia.
Therefore,
is not Therefore, YESCARTA is not
may cause
toxicity, including
B-cell YESCARTA
lymphocytopenia.
in this section reflect exposure to YESCARTA in the clinical trial (Study 1) in which 108 patients
with relapsed/
recommended
for women who
are pregnant,for
andwomen
pregnancy
afterpregnant,
YESCARTA
should
beYESCARTA
discussed infusion should be discussed
recommended
who are
andinfusion
pregnancy
after
refractory B-cell NHL received CAR-positive T cells based on a recommended dose which
was weight-based
with the treatingischemia)
physician. Inwith
the U.S.
general physician.
population,Inthe
background
risktheofestimated
major birthbackground risk of major birth
the treating
theestimated
U.S. general
population,
. Patients
[seewith
Clinical
a history
Trialsof(14)]
CNS. Patients
disorderswith
(such
a history
as seizures
of CNSordisorders
cerebrovascular
(such asischemia)
seizures or cerebrovascular
defects
and miscarriage
in clinically
pregnancies
is 2%recognized
- 4% and pregnancies
15% - 20%, respectively.
defectsrecognized
and miscarriage
in clinically
is 2% - 4% and 15% - 20%, respectively.
or autoimmune disease requiring systemic immunosuppression were ineligible. The median
duration
of
follow up was 8.7 months. The median age of the study population was 58 years (range:
to 76 years);
8.223Lactation:
Risk68%
Summary:
is no information
regarding
presence
of YESCARTA
human
milk, of YESCARTA in human milk,
8.2There
Lactation:
Risk Summary:
Therethe
is no
information
regardingin the
presence
were men. The baseline ECOG performance status was 43% with ECOG 0, and 57% with
Thethemost
theECOG
effect1.on
breastfed infant,
and the
on milkinfant,
production.
developmental
and healthThe
benefits
the effect
on effects
the breastfed
and theThe
effects
on milk production.
developmental and health benefits
common adverse reactions (incidence ≥ 20%) include CRS, fever, hypotension, encephalopathy,
tachycardia,
of breastfeeding
should be considered
along with
the be
mother's
clinical
needwith
for the
YESCARTA
any potential
of breastfeeding
should
considered
along
mother'sand
clinical
need for YESCARTA and any potential
fatigue, headache, decreased appetite, chills, diarrhea, febrile neutropenia, infections-pathogen
unspecified,
adverse effects
on the breastfed
infanteffects
from YESCARTA
or frominfant
the underlying
maternal
condition.
adverse
on the breastfed
from YESCARTA
or from
the underlying maternal condition.
nausea, hypoxia, tremor, cough, vomiting, dizziness, constipation, and cardiac arrhythmias. Serious adverse
8.3
Females
and
Males
of
Reproductive
Potential:
Pregnancy
Testing:
Pregnancy
status
of
females
8.3
Females
and
Males
of
Reproductive
Potential:
Pregnancy
Testing: with
Pregnancy status of females with
reactions occurred in 52% of patients. The most common serious adverse reactions (> 2%) include
potential
be verified. Sexually-active
of reproductive
potential
should
have a
potential shouldfemales
be verified.
Sexually-active
females
of reproductive
potential should have a
encephalopathy, fever, lung infection, febrile neutropenia, cardiac arrhythmia, cardiacreproductive
failure, urinary
tract should reproductive
pregnancy
test prior to starting
treatmenttest
with
YESCARTA.
Contraception:
pregnancy
prior
to starting
treatment with
Contraception:
SeeYESCARTA.
the prescribing
informationSee the prescribing information
infection, renal insufficiency,
Clostridium
aphasia,
difficile
cardiac
infection,
arrest, Clostridium
delirium, hypotension,
difficile infection, delirium,
hypotension,
for fludarabine
and cyclophosphamide
for information
on the need forfor
effective
contraception
in patients
who contraception in patients who
for fludarabine
and cyclophosphamide
information
on the need
for effective
and hypoxia. The most common (≥ 10%) Grade 3 or higher reactions include febrile neutropenia,
fever,
receive
the lymphodepleting
chemotherapy.
There are insufficient
exposureThere
data are
to provide
a recommendation
receive the lymphodepleting
chemotherapy.
insufficient
exposure data to provide a recommendation
CRS, encephalopathy, infections-pathogen unspecified, hypotension, hypoxia, and lung
infections.
Forty-five
concerning duration of contraception
following
treatment
with YESCARTA.
concerning
duration
of contraception
following
treatment
withareYESCARTA.
Infertility:
There
no data onInfertility:
the
There are no data on the
percent (49/108) of patients received tocilizumab after infusion of YESCARTA.
effect of YESCARTA on fertility.effect of YESCARTA on fertility.
Summary of Adverse Reactions Observed in at Least 10% of the Patients Treated with YESCARTA
8.4 Pediatric Use: The safety8.4
andPediatric
efficacy of
YESCARTA
have
been established
in have
pediatric
patients.
Use:
The safety
andnotefficacy
of YESCARTA
not been
established in pediatric patients.
in Study 1
Adverse Reaction

Adverse Reaction

Any Grade
(%)

Tachycardia
Cardiac disorders
Arrhythmia

Tachycardia 57
Arrhythmia 23

Diarrhea
Gastrointestinal
disorders
Nausea
Vomiting
Constipation
Abdominal pain
Dry mouth

38
Diarrhea
34
Nausea
26
Vomiting
Constipation 23
14
Abdominal pain
Dry mouth 11

Fever and
General disorders
Fatigue
administration
site conditions
Chills
Edema

Fever
Fatigue
Chills
Edema

86
46
40
19

Geriatric
Use: 3Clinical
YESCARTA
didClinical
not include
numbers
patientssufficient
aged 65 numbers
years of patients aged 65 years
8.5ofGeriatric
Use:
trials sufficient
of YESCARTA
did notof include
Grades 3 or Any8.5
Grade
Grades
or trials
and older toHigher
determine
differently
or have
outcomes
as compared
to outcomes as compared to
andthey
olderrespond
to determine
whether
theydifferent
respondsafety
differently
or have
different safety
Higher (%)
(%)
(%) whether
younger patients.
younger patients.
2
57
2
17
INFORMATION
17 PATIENT COUNSELING INFORMATION
7
23 PATIENT COUNSELING
7
Advise the patient to read theAdvise
FDA-approved
labeling
(Medication Guide).
patients Guide). Ensure that patients
the patientpatient
to read
the FDA-approved
patient Ensure
labelingthat
(Medication
4
4 of manufacturing
38
understand
the risk
failure
(1%ofinmanufacturing
clinical trial). Infailure
case of
a manufacturing
understand
the risk
(1%
in clinical trial).failure,
In casea of a manufacturing failure, a
0
0
34
second
manufacturing
of YESCARTA
may be attempted.
In addition,
while
the patientInawaits
the product,
second manufacturing
of YESCARTA
may
be attempted.
addition,
while the patient awaits the product,
1
1
26
additional
chemotherapy
(notadditional
the lymphodepletion)
may
necessary
and may increase
the risk ofand may increase the risk of
chemotherapy
(notbethe
lymphodepletion)
may be necessary
0
0
23
adverse
events during
the pre-infusion
period.
Advise
to seek
immediate
forseek
any of
the
adverse events
during
thepatients
pre-infusion
period.
Advise attention
patients to
immediate
attention for any of the
1
1 Release Syndrome,
14
following:
Cytokine
Neurologic
Toxicities,
SeriousNeurologic
Infections,Toxicities,
ProlongedSerious
Cytopenia
[see Prolonged Cytopenia [see
following: Cytokine
Release
Syndrome,
Infections,
0
0
11
Warnings
and Precautions
(5.1,
5.2, 5.3,
and Adverse
more
information
and (6)
signs
Warnings
and5.5)
Precautions
(5.1,Reactions
5.2, 5.3,(6)
5.5)forand
Adverse
Reactions
for more information and signs
and
the need Advise
to: Refrain
from for
driving
or operating
heavy
potentially
and for
symptoms].
patients
the need
to: Refrain
fromordriving
or operating heavy or potentially
16
86 symptoms].16Advise patients
dangerous
machinery
after YESCARTA
untilafter
at least
8 weeks
after infusion
and infusion [see Warnings and
dangerousinfusion
machinery
YESCARTA
infusion
until at [see
leastWarnings
8 weeks after
3
3
46
Precautions
(5.2)],
monitoring
of blood
counts. Contact
Kiteofatblood
1-844-454-KITE
(5483)
Precautions
(5.2)],
Have periodic
monitoring
counts. Contact
Kiteif at 1-844-454-KITE (5483) if
0
0 Have periodic
40
they
malignancywith
[seeaWarnings
Precautions
they are diagnosed
secondaryand
malignancy
[see(5.8)].
Warnings and Precautions (5.8)].
1
1 with a secondary
19 are diagnosed

Cytokine
release syndrome Cytokine release
94 syndrome 13
Immune system
disorders
Hypogammaglobulinemia Hypogammaglobulinemia
15
0
16
26
Infections-pathogen
Infections and
infestations unspecified
Infections-pathogen
unspecified
4
16
Viral infections
Viral infections
9
13
Bacterial infections
Bacterial infections
Decreased appetite
Investigations
Weight decreased
Dehydration

44
Decreased appetite
16
Weight decreased
Dehydration 11

2
0
3

94
Manufactured
by,13Packed by, Distributed
by: Kite
Pharma,by,Inc.,
Santa Monica,
90404 Inc., Santa Monica, CA 90404
Manufactured
by, Packed
Distributed
by: KiteCAPharma,
15 License No 2064
0
US
US License No 2064
16
26
YESCARTA
is a trademark
of Kite
Pharma.is a trademark of Kite Pharma.
YESCARTA
4
16
©
2017
Kite
Pharma
|
PRC-00104
11/2017
©
2017
Kite Pharma | PRC-00104 11/2017
9
13
44
16
11

2
0
3

11/2/17 12:42 PM

11/2/17 12:42 PM

11/3/17 4:21 PM



Table of Contents for the Digital Edition of ASH News Daily 2017 - Issue 1

ASH News Daily 2017 - Issue 1 - A-1
ASH News Daily 2017 - Issue 1 - A-2
ASH News Daily 2017 - Issue 1 - A-3
ASH News Daily 2017 - Issue 1 - A-4
ASH News Daily 2017 - Issue 1 - A-5
ASH News Daily 2017 - Issue 1 - A-6
ASH News Daily 2017 - Issue 1 - A-7
ASH News Daily 2017 - Issue 1 - A-8
ASH News Daily 2017 - Issue 1 - A-9
ASH News Daily 2017 - Issue 1 - A-10
ASH News Daily 2017 - Issue 1 - A-11
ASH News Daily 2017 - Issue 1 - A-12
ASH News Daily 2017 - Issue 1 - A-13
ASH News Daily 2017 - Issue 1 - A-14
ASH News Daily 2017 - Issue 1 - A-15
ASH News Daily 2017 - Issue 1 - A-16
ASH News Daily 2017 - Issue 1 - A-17
ASH News Daily 2017 - Issue 1 - A-18
ASH News Daily 2017 - Issue 1 - A-19
ASH News Daily 2017 - Issue 1 - A-20
ASH News Daily 2017 - Issue 1 - A-21
ASH News Daily 2017 - Issue 1 - A-22
ASH News Daily 2017 - Issue 1 - A-23
ASH News Daily 2017 - Issue 1 - A-24
ASH News Daily 2017 - Issue 1 - A-25
ASH News Daily 2017 - Issue 1 - A-26
ASH News Daily 2017 - Issue 1 - A-27
ASH News Daily 2017 - Issue 1 - A-28
ASH News Daily 2017 - Issue 1 - B-1
ASH News Daily 2017 - Issue 1 - B-2
ASH News Daily 2017 - Issue 1 - B-3
ASH News Daily 2017 - Issue 1 - B-4
ASH News Daily 2017 - Issue 1 - B-5
ASH News Daily 2017 - Issue 1 - B-6
ASH News Daily 2017 - Issue 1 - B-7
ASH News Daily 2017 - Issue 1 - B-8
ASH News Daily 2017 - Issue 1 - B-9
ASH News Daily 2017 - Issue 1 - B-10
ASH News Daily 2017 - Issue 1 - B-11
ASH News Daily 2017 - Issue 1 - B-12
ASH News Daily 2017 - Issue 1 - B-13
ASH News Daily 2017 - Issue 1 - B-14
ASH News Daily 2017 - Issue 1 - B-15
ASH News Daily 2017 - Issue 1 - B-16
ASH News Daily 2017 - Issue 1 - B-17
ASH News Daily 2017 - Issue 1 - B-18
ASH News Daily 2017 - Issue 1 - B-19
ASH News Daily 2017 - Issue 1 - B-20
ASH News Daily 2017 - Issue 1 - B-21
ASH News Daily 2017 - Issue 1 - B-22
ASH News Daily 2017 - Issue 1 - B-23
ASH News Daily 2017 - Issue 1 - B-24
ASH News Daily 2017 - Issue 1 - B-25
ASH News Daily 2017 - Issue 1 - B-26
ASH News Daily 2017 - Issue 1 - B-27
ASH News Daily 2017 - Issue 1 - B-30
ASH News Daily 2017 - Issue 1 - B-31
ASH News Daily 2017 - Issue 1 - B-32
ASH News Daily 2017 - Issue 1 - B-33
ASH News Daily 2017 - Issue 1 - B-34
ASH News Daily 2017 - Issue 1 - B-35
ASH News Daily 2017 - Issue 1 - B-36
ASH News Daily 2017 - Issue 1 - B-37
ASH News Daily 2017 - Issue 1 - B-38
ASH News Daily 2017 - Issue 1 - B-39
ASH News Daily 2017 - Issue 1 - B-40
ASH News Daily 2017 - Issue 1 - B-41
ASH News Daily 2017 - Issue 1 - B-42
ASH News Daily 2017 - Issue 1 - B-43
ASH News Daily 2017 - Issue 1 - B-44
ASH News Daily 2017 - Issue 1 - B-45
ASH News Daily 2017 - Issue 1 - B-46
ASH News Daily 2017 - Issue 1 - B-47
ASH News Daily 2017 - Issue 1 - B-48
ASH News Daily 2017 - Issue 1 - B-49
ASH News Daily 2017 - Issue 1 - B-50
ASH News Daily 2017 - Issue 1 - B-51
ASH News Daily 2017 - Issue 1 - B-52
ASH News Daily 2017 - Issue 1 - B-53
ASH News Daily 2017 - Issue 1 - B-54
ASH News Daily 2017 - Issue 1 - B-55
ASH News Daily 2017 - Issue 1 - B-56
ASH News Daily 2017 - Issue 1 - C-1
ASH News Daily 2017 - Issue 1 - C-2
ASH News Daily 2017 - Issue 1 - C-3
ASH News Daily 2017 - Issue 1 - C-4
ASH News Daily 2017 - Issue 1 - C-5
ASH News Daily 2017 - Issue 1 - C-6
ASH News Daily 2017 - Issue 1 - C-7
ASH News Daily 2017 - Issue 1 - C-8
ASH News Daily 2017 - Issue 1 - C-9
ASH News Daily 2017 - Issue 1 - C-10
ASH News Daily 2017 - Issue 1 - C-11
ASH News Daily 2017 - Issue 1 - C-12
ASH News Daily 2017 - Issue 1 - C-13
ASH News Daily 2017 - Issue 1 - C-14
ASH News Daily 2017 - Issue 1 - C-15
ASH News Daily 2017 - Issue 1 - C-16
ASH News Daily 2017 - Issue 1 - C-17
ASH News Daily 2017 - Issue 1 - C-18
ASH News Daily 2017 - Issue 1 - C-19
ASH News Daily 2017 - Issue 1 - C-20
ASH News Daily 2017 - Issue 1 - C-21
ASH News Daily 2017 - Issue 1 - C-22
ASH News Daily 2017 - Issue 1 - C-23
ASH News Daily 2017 - Issue 1 - C-24
ASH News Daily 2017 - Issue 1 - C-25
ASH News Daily 2017 - Issue 1 - C-26
ASH News Daily 2017 - Issue 1 - C-27
ASH News Daily 2017 - Issue 1 - C-28
ASH News Daily 2017 - Issue 1 - C-29
ASH News Daily 2017 - Issue 1 - C-30
ASH News Daily 2017 - Issue 1 - C-31
ASH News Daily 2017 - Issue 1 - C-32
https://www.nxtbookmedia.com